期刊文献+

胰腺癌组织端粒酶逆转录酶的表达及其与临床病理的关系 被引量:5

Expression of Human Telomerase Reverse Transcriptase and its Correlation with Clinical Pathological Features in Patients with Pancreatic Cancer
原文传递
导出
摘要 目的研究人端粒酶逆转录酶(hHERT)在胰腺癌组织中的表达及其与临床病理的关系。方法描述胰腺癌的部位、大小、组织分级和临床分明,用SABC免疫组化方法检测hTERT的表达。结果hTERT在胰腺癌组织中表达的阳性率为81.6%,在慢性胰腺炎和正常胰腺组织中表达为0,差异有显著性(P<0.001)。hTERT的表达与肿瘤的部位、大小和组织分级无关(P>0.05),与临床分期有关(P<0.05)。结论hTERT在胰腺癌组织中有较高表达,与临床分期有关。故可以此鉴别胰腺癌和慢性胰腺炎。 Objectivev To investigate the expression of human telomerase reverse transcriptase (hTERT) and its correlation with features of clinical pathology in patients with pancreatic cancer. Methods The sites,size,histological classifications and clinical stages of the tumors were noted. Expression of hTERT was measured by SABC. Results The positive expression rate of hTERT was 81.6% in pancreatic cancer tissues, but none in chronic pancreatitis tissues and normal pancreatic tissuse (P<0.001). Expression of hTERT had to do with clinical stages(P<0.005), but not to do with site,size and histological classification(P>0.05). Conclusion There is higher expression of hTERT in pancreatic cancer tissues than in thers. Expression of hTERT is correlated with its clinical stages. Expression of hTERT can distinguish pancreatic cancer from chronic pancreatitis.
出处 《临床消化病杂志》 2005年第2期65-66,共2页 Chinese Journal of Clinical Gastroenterology
基金 广州市委基金资助(No.30000198) 中山大学附属第二医院基金资助(F002000074)
关键词 端粒酶逆转录酶 胰腺癌 病理 免疫组织化学 hTERT Pancreatic cancer Pathology Immunohistochemisty
  • 相关文献

参考文献9

  • 1Pakinson EK. Do telomerase antagonists represent a novel anti-cancer strategy[J] ? Br J Cancer,1996,71 ( 1 ) :1.
  • 2Sobin LH, Wittekind CH. TNM classification of malignant turnouts. In: International Union Against Cancer ( UCC ) [ M ]. 5th ed, New York: John Wiley, 1997,87.
  • 3Kloppel G, Solcia E, Longnecker DS, et al. Histological typing of tumnouts of the exocrine pancreas. In: World Health Organization international histological classification of tumours[ M ]. 2nd ed, New York: Springer, 1996.15.
  • 4Rhyu MS. Telomeres, telomerase and immortality [ see comments ][J]. J Natl Cancer Inst, 1995,87 (12) :884.
  • 5Blasco MA, Rize M, Greider CW, et al. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. [ J] Nature Genet,1996,12(2) :200.
  • 6Avilion AA, Piatyszek MA, Gupta J, et al. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissures. [ J] Cancer Res, 1996,56 ( 3 ) :645.
  • 7Weinrich S,Pruzna R,Ma L,et al. Recomstitution of human telomerase with the template RNA component h-TR and the catalytic protein subunit h-TRT[ J ]. Nat Gdenet, 1997,17 (4) :498.
  • 8Harrington L,Zhou W,Mcphail T,et al. Human telomerase comtains evolutionarily conserved catalytic and structural subunits[ J ]. Genes Der, 1997,11 (23) :3109.
  • 9Tahama H,Yasui W,Tahara E,et al. Immuno-histochemical detection of human telomerasw catalytic compoenet, h-TERT in humancolorectal and non-tumor tissue sections [ J ]. Oncogene, 1999, 18(8) :1561.

同被引文献53

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部